Abstract:Transforming growth factor-b (TGF-b) was initially discovered by its ability to stimulate immortalized fibroblasts to grow in soft agar, a phenotype associated with expressing cancer-causing genes. Subsequently, it became clear that the ‘‘transforming activity’’ of TGF-b is reversible and can have potent cytostatic effects on normal epithelial cells. TGF-b is now well known for its dual effects in cancer progression; while TGF-b can have suppressive effects on normal and premalignant cells, more advanced cancer cells—frequently exposed to high levels of TGF-b produced by themselves or the stroma—are not only resistant to its cytostatic effects but also stimulated in their invasive and metastatic behavior. TGF-b can do this directly by facilitating epithelial tomesenchymal transition (EMT) and indirectly by acting on its surrounding stroma, promoting angiogenesis and immune evasion (Akhurst and Derynck, 2001). TGF-b signals via cell surface TGF-b type I and type II serine threonine kinase receptors and intracellular SMAD effector proteins. Upon TGF-b receptor activation, SMAD2 and SMAD3 become phosphorylated and form heteromeric complexes with SMAD4. These SMAD complexes can accumulate in the nucleus, where they act as transcriptional regulators. Because SMAD2 does not interact with DNA and the affinity of SMAD3 and SMAD4 for DNA is weak, there is a need for SMADs to partner with other DNAbinding transcription factors. The repertoire of SMAD interaction partners is large and diverse, providing a basis for multi-functionality of TGF-b and its context-dependent effects (Massagué, 2012). TGF-b receptors and SMADs are mutated in certain cancers. Inactivation of tumor suppressor genes, activation of proto-oncogenes, and microenvironmental changes can change the tumor suppressive and the tumor promoting activity of the TGF-b receptor/SMAD pathway. Most cancer patients die of metastasis and, because TGF-b is a strong driver of this process, TGF-b pathway inhibiting agents have been developed and tested in clinical trials. However, these compounds inhibit all TGF-b responses and may elicit unwanted effects. Careful selection of patients is warranted and proper biomarkers are needed to select those patients that will benefit from such systemic TGF-b-targeted therapy. A better understanding of the molecular mechanisms underlying the contextual effects of TGF-b in cancer may allow development of therapeutics selectively inhibiting its pro-oncogenic effects. Previously, Yu and colleagues provided some clues on these mechanisms by demonstrating that the phosphoserine/phosphothreonine-binding protein 14-3-3z, which is overexpressed in more than 40% of breast cancers, can potentiate TGF-b/ SMAD signaling during EMT and breast tumor progression (Lu et al., 2009). 14-33z and the tyrosine kinase receptor ErbB2 were found to cooperate in driving non-invasive ductal carcinoma in situ (DCIS) progression to invasive breast ductal carcinoma (IDC). Breast tumors expressing both ErbB2 and 14-3-3z have a higher incidence of metastasis than those expressing only one of them (Lu et al., 2009). In addition, they found 143-3z downregulated the cell cycle inhibitor p27 and activated phosphoinositide 3-kinase, thereby promoting cancer cell proliferation and survival (Rehman et al., 2014 and references therein).

Tgf Beta Signaling In Pancreatic Ductal Adenocarcinoma

Methyl-CpG-binding Domain 3 Inhibits Epithelial–mesenchymal Transition in Pancreatic Cancer Cells Via TGF-β/Smad Signalling

Methyl-CpG-binding Protein 2 Drives the Furin/TGF-β1/Smad Axis to Promote Epithelial–mesenchymal Transition in Pancreatic Cancer Cells

TGF-β inhibits growth of pancreatic ductal epithelial cells through receptor-mediated activation of Smad proteins

Tumor-stroma TGF-β1-THBS2 feedback circuit drives pancreatic ductal adenocarcinoma progression via integrin αvβ3/CD36-mediated activation of the MAPK pathway

Abrogation of Transforming Growth Factor- Β Signaling in Pancreatic Cancer

TGF-β Signaling Loop in Pancreatic Ductal Adenocarcinoma Activates Fibroblasts and Increases Tumor Cell Aggressiveness

TGF-β Tumor Suppression Through a Lethal EMT

Inhibition of Transforming Growth Factor β Signaling Reduces Pancreatic Adenocarcinoma Growth and Invasiveness

TGF-β in Pancreatic Cancer Initiation and Progression: Two Sides of the Same Coin

Targeting TGFβR2‐mutant Tumors Exposes Vulnerabilities to Stromal TGFβ Blockade in Pancreatic Cancer

In Vivo Disruption Of Tgf-Beta Signaling By Smad7 Leads To Premalignant Ductal Lesions In The Pancreas

Overexpressed integrin alpha 2 inhibits the activation of the transforming growth factor β pathway in pancreatic cancer via the TFCP2-SMAD2 axis

The role of TGF-β/SMAD4 signaling in cancer

Trefoil Factor 3 Promotes Pancreatic Carcinoma Progression Via WNT Pathway Activation Mediated by Enhanced WNT Ligand Expression

Transforming growth factor- challenge alters the <i>N</i>-, <i>O</i>-, and glycosphingolipid glycomes in PaTu-S pancreatic adenocarcinoma cells

Transforming Growth Factor Beta Suppresses Beta-Catenin/Wnt Signaling and Stimulates an Adhesion Response in Human Colon Carcinoma Cells in A Smad4/Dpc4 Independent Manner

Biomarkers of TGF-β Signaling Pathway and Prognosis of Pancreatic Cancer

Cancer Cell Previews 14-3-3 z Turns TGF-b to the Dark Side

Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1

TGF-β Signaling Pathway1S Function in Tumor Initiation, Progression and Metastasis